Molecule structure of Escitalopram oxalate (CAS NO.219861-08-2):
 

IUPAC Name: (1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; oxalic acid 
Molecular Weight: 414.426823 g/mol
Molecular Formula: C₂₂H₂₃FN₂O₅ 
Melting Point: 152-153 °C
Boiling Point: 428.3 °C at 760 mmHg
Flash Point: 212.8 °C
Enthalpy of Vaporization: 68.35 kJ/mol
Vapour Pressure: 1.53E-07 mmHg at 25 °C
H-Bond Donor: 2
H-Bond Acceptor: 8
Rotatable Bond Count: 6
Exact Mass: 414.1591
MonoIsotopic Mass: 414.1591
Topological Polar Surface Area: 111
Heavy Atom Count: 30 
Complexity: 537
Defined Atom StereoCenter Count: 1
Canonical SMILES: CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
Isomeric SMILES: CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
InChI: InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)/t20-;/m0./s1
InChIKey: KTGRHKOEFSJQNS-BDQAORGHSA-N
Product Categories: Antidepressant; Heterocyclic Compounds; Intermediates & Fine Chemicals; Neurochemicals; Pharmaceuticals; Isotope Labeled Compounds; Escitalopram

 Escitalopram oxalate (219861-08-2) was developed in the cooperation between Forest Laboratories and Lundbeck. Its development began in the summer of 1997, and the resulting new drug application was submitted to the U.S. Food and Drug Administration (FDA) in March 2001.Because of the previous extensive experience of Lundbeck and Forest with citalopram,it only took 3.5 years to develop escitalopram.The FDA issued the approval of escitalopram for generalized anxiety disorder in December 2003 and major depression in August 2002. Escitalopram can be considered an example of the strategy pharmaceutical companies use in order to extend a drug's lifetime, in this case of the citalopram franchise. Escitalopram is an enantiopure compound of the racemic mixture citalopram, used for the same indication, and for that reason it required less investment and less time to develop. Two years after escitalopram's launch, when the patent on citalopram expired, the escitalopram sales successfully made up for the loss. On May 23, 2006, the FDA approved a generic version of escitalopram by Teva.On July 14 of that year, however, the U.S. District Court of Delaware decided in favor of Lundbeck regarding the patent infringement dispute and ruled the patent on escitalopram valid.In 2006 Forest Laboratories was granted an 828 day extension on its patent for escitalopram. The patent expiry was pushed  from December 7, 2009 to March 14, 2012.

 Escitalopram oxalate (CAS NO.219861-08-2) is used as an inhibitor of serotonin (5-HT) uptake.

Hazard Codes: Xi
Risk Statements: 36/37/38 
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 26-36 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36:Wear suitable protective clothing.

 Escitalopram oxalate (CAS NO.219861-08-2) is also named as Cipralex ; Lexapro ; Lu 26-054-0 ; S-(+)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate ; S-(+)-5-Isobenzofurancarbonitrile, 1-(3-
(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, oxalate ; UNII-5U85DBW7LO ; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1) . Escitalopram oxalate (CAS NO.219861-08-2) is white solid. It is soluble in methanol and dimethyl sulfoxide, dissolved in saline, slightly soluble in water and ethanol, slightly soluble in ethyl acetate, insoluble in heptane.